Conference reports

Antiviral activity of foscarnet in salvage patients

Novel strategies with existing drugs

Antiretroviral activity of new and novel agents

Overview of pharmacology studies

Incidence of TB infection despite HAART and treatment in coinfected patients

Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

Does WHO clinical stage reliably predict who should receive ARV treatment?

Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

Keystone vaccine symposia 2005: vaccines, pathogenesis, snow and a couple of elk

14th International HIV Drug Resistance Workshop (14th IHDRW), 7-11 June 2005, Quebec City, Canada

Genetic factors affecting HIV infection and progression rates: immunological factors relating to entry inhibitors

Resistance during MTCT strategies: new data on protective benefit of Combivir added to single-dose nevirapine, and impact of treatment and breastfeeding on the infant

Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs

Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure

Predicting clinical responses to ddI from genotypic resistance

Under-detection of transmission of transmitted resistance and impact on treatment response

Risk of death in UK after diagnosis of 3-class resistance

11th BHIVA and BASSH joint annual conference, 22-25 April 2005, Dublin

Long-awaited UK pregnancy guidelines now updated; pregnancy studies in Dublin

Underdosing of ARVs in children: results from CHIPS cohort

Sexual transmission and response to treatment in acute HCV infection in HIV-positive gay men coinfected with HIV

Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin

Schistosomiasis after immune reconstitution: symptoms appear as HAART side effects

6th International Workshop on Clinical Pharmacology of HIV Therapy, 28-30 April 2005, Quebec, Canada

Effect of age/menopause on lopinavir and efavirenz concentrations in women

Effect of age on lopinavir concentrations

Gender and pharmacokinetics of saquinavir

Dosing nevirapine in children

Intracellular NRTI-triphosphate levels in children are similar to adults

Efavirenz and rifampicin: lower body weight associated with higher concentrations

Summary of drug-drug interaction studies

Responses to atazanavir, Kaletra and side effects

3rd European HIV Drug Resistance Workshop, 30 March-1 April 2005, Athens

Tenofovir, nucleosides, and non-nucleosides

Protease inhibitors

CCR5 antagonists

Paediatric reports from 12th Conference on Retrovirus and Opportunistic Infections (CROI)

Once-daily lopinavir/ritonavir for children may offer advantages

Lopinavir/ritonavir for young infants

Paediatric dose finding atazanavir and atazanavir/ritonavir

Switching d4T to tenofovir and protease inhibitor to efavirenz

12th Conference on Retrovirus and Opportunistic Infections, 22-25 February, Boston, 2005

Developments in nevirapine use in MTCT reduction

Mashi study – late breakers on breastfeeding

Maternal health and infant mortality

Paediatric care in lower income settings

Tenofovir not linked to bone toxicity in children followed for one year

Gut memory CD4 T cells implicated in a central role for HIV disease pathology: dramatic impact prior to seroconversion

Case of multi-drug resistant (MDR) rapid progressor

Case report of antibody reversion and negative viral load four-years after treatment discontinuation

24-week efficacy of TMC114 in PI-experienced patients

Maturation inhibitor shows anti-HIV activity in single dose pilot study

New antiretrovirals at 12th CROI

Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age

Omega-3 supplement effective to reduce triglycerides

Entecavir is effective against 3TC-resistant hepatitis B

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

Tenofovir is non-inferior to adefovir for the treatment of hepatitis B in HBV-HIV co-infected patients

7th International Congress on Drug Therapy in HIV Infection (ICDTHI), 14-18 November 2004, Glasgow

Nandrolone decanoate combats HIV-related weight loss: results from three randomised studies

Atazanavir boosts intracellular saquinavir levels: data on important new dual-boosted regimen

Marked variability in plasma atazanavir levels: importance of ritonavir boosting and TDM

Effective switching to atazanavir/ritonavir in clinical practice

Post navigation